Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.
Cancer Lett
; 365(2): 149-55, 2015 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-25888452
ABSTRACT
The treatment of rhabdomyosarcoma (RMS) is challenging, and the prognosis remains especially poor for high-grade RMS with metastasis. The conventional treatment of RMS is based on multi-agent chemotherapy combined with resection and radiotherapy, which are often marked by low success rate. Alternative therapeutic options include the combination of standard treatments with immunotherapy. We generated a microtubule-associated protein (MAP)-based fully human cytolytic fusion protein (hCFP) targeting the fetal acetylcholine receptor, which is expressed on RMS cells. We were able to express and purify functional scFv35-MAP from Escherichia coli cells. Moreover, we found that scFv35-MAP is rapidly internalized by target cells after binding its receptor, and exhibits specific cytotoxicity toward FL-OH1 and RD cells in vitro. We also confirmed that scFv35-MAP induces apoptosis in FL-OH1 and RD cells. The in vivo potential of scFv35-MAP will need to be considered in further studies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rabdomiossarcoma
/
Proteínas Recombinantes de Fusão
/
Apoptose
/
Antagonistas Colinérgicos
/
Proteínas Associadas aos Microtúbulos
Limite:
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article